{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:12:19Z","timestamp":1785892339709,"version":"3.56.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"European LeukemiaNet, the Nordic CML Study Group"},{"name":"The Swedish State Support (ALF)"},{"name":"The Medical Faculty at Uppsala University"},{"DOI":"10.13039\/100002491","name":"Bristol-Meyers Squibb","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.leukres.2016.09.019","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T10:13:51Z","timestamp":1475144031000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli"],"prefix":"10.1016","volume":"50","author":[{"given":"Stina","family":"S\u00f6derlund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christiansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Loskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2016.09.019_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.leukres.2016.09.019_bib0010","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2016.09.019_bib0015","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2016.09.019_bib0020","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2016.09.019_bib0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2016.09.019_bib0030","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2016.09.019_bib0035","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2016.09.019_bib0040","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2016.09.019_bib0045","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","article-title":"Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2016.09.019_bib0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11899-013-0190-1","article-title":"Immunology and immunotherapy of chronic myeloid leukemia","volume":"9","author":"Ilander","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"7","key":"10.1016\/j.leukres.2016.09.019_bib0055","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/leu.2013.19","article-title":"Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2016.09.019_bib0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrd2006","article-title":"Multiplexed protein measurement: technologies and applications of protein and antibody arrays","volume":"5","author":"Kingsmore","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.leukres.2016.09.019_bib0065","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ejh.12423","article-title":"Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)","volume":"94","author":"Hjorth-Hansen","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2016.09.019_bib0070","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in good-risk chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"0","key":"10.1016\/j.leukres.2016.09.019_bib0075","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.euprot.2014.02.002","article-title":"The use of multiplex platforms for absolute and relative protein quantification of clinical material","volume":"3","author":"Christiansson","year":"2014","journal-title":"EuPA Open Proteomics"},{"issue":"9","key":"10.1016\/j.leukres.2016.09.019_bib0080","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2016.09.019_bib0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz Greg","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.leukres.2016.09.019_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncolgy meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen Daniel","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.leukres.2016.09.019_bib0095","doi-asserted-by":"crossref","first-page":"e28925","DOI":"10.4161\/onci.28925","article-title":"Dasatinib promotes Th1-type responses in granzyme B expressing T-cells","volume":"3","author":"Kreutzman","year":"2014","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.leukres.2016.09.019_bib0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s002620050270","article-title":"Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro","volume":"42","author":"Pawelec","year":"1996","journal-title":"Cancer Immunol."},{"issue":"5","key":"10.1016\/j.leukres.2016.09.019_bib0105","first-page":"1671","article-title":"Restoration of th1 cytokine synthesis by t cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-\u03b1","volume":"6","author":"Reuben","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2016.09.019_bib0110","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1535-7163.MCT-14-0849","article-title":"The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses","volume":"14","author":"Christiansson","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2016.09.019_bib0115","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1146\/annurev.iy.12.040194.004313","article-title":"The CD40 antigen and its ligand","volume":"12","author":"Banchereau","year":"1994","journal-title":"Annu. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.leukres.2016.09.019_bib0120","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3109\/10428194.2011.647017","article-title":"Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib","volume":"53","author":"Hayashi","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.leukres.2016.09.019_bib0125","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2016.09.019_bib0130","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2005-02-0479","article-title":"The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D\u2013target-cell interactions","volume":"106","author":"Sconocchia GLMPMRKWWFHHNMJLJFSBAJ","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2016.09.019_bib0135","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","article-title":"Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes","volume":"96","author":"Aguayo","year":"2000","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2016.09.019_bib0140","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V95.8.2637","article-title":"Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia","volume":"95","author":"Padr\u00f3","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2016.09.019_bib0145","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","article-title":"Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia","volume":"19","author":"Schmidt","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.leukres.2016.09.019_bib0150","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/00365510701854991","article-title":"Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia","volume":"68","author":"Zhelyazkova","year":"2008","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"7","key":"10.1016\/j.leukres.2016.09.019_bib0155","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1593\/neo.12724","article-title":"Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression","volume":"14","author":"Cerny-Reiterer","year":"2012","journal-title":"Neoplasia (New York, NY)"},{"issue":"10","key":"10.1016\/j.leukres.2016.09.019_bib0160","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1080\/10428190701540975","article-title":"VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues","volume":"48","author":"Bardelli","year":"2007","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2016.09.019_bib0165","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.bjc.6603966","article-title":"Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia","volume":"97","author":"Lee","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.leukres.2016.09.019_bib0170","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2013-11-538694","article-title":"Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche","volume":"123","author":"Krause","year":"2014","journal-title":"Blood"},{"issue":"7281","key":"10.1016\/j.leukres.2016.09.019_bib0175","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.leukres.2016.09.019_bib0180","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1152\/nips.01452.2003","article-title":"Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow","volume":"18","author":"Wodnar-Filipowicz","year":"2003","journal-title":"Physiology"},{"issue":"7","key":"10.1016\/j.leukres.2016.09.019_bib0185","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/1078-0432.CCR-07-5134","article-title":"Regulation of hematopoietic stem cells by the steel factor\/KIT signaling pathway","volume":"14","author":"Kent","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.leukres.2016.09.019_bib0190","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood-2003-10-3443","article-title":"Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib","volume":"103","author":"Bono","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2016.09.019_bib0195","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1182\/blood-2006-01-023127","article-title":"Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches","volume":"108","author":"Greiner","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2016.09.019_bib0200","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.leukres.2016.09.019_bib0205","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000226288","article-title":"Does imatinib mesylate therapy cause growth hormone deficiency?","volume":"18","author":"Kebapcilar","year":"2009","journal-title":"Med. Princ. Pract."},{"issue":"2","key":"10.1016\/j.leukres.2016.09.019_bib0210","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1210\/jcem.83.2.4594","article-title":"Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee","volume":"83","author":"Carroll","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.leukres.2016.09.019_bib0215","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/sj.leu.2403250","article-title":"CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review","volume":"18","author":"Bene","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.09.019_bib0220","unstructured":"K.-S. Ahn, J.-W. Park, Y.-J. Kim, S. Park, B.-K. Kim, S.-S. Yoon, et al., FLT3, CD32, PU.1 ERG, uPAR, and TAP2 are strongly associated with the progression of chronic myeloid leukemia and combination of small interference RNA of TAP2 and STI571 synergistically induced the apoptosis in K562 cells. AACR Meeting Abstracts. (2006) 2006 (1):432."},{"issue":"24","key":"10.1016\/j.leukres.2016.09.019_bib0225","first-page":"7126","article-title":"Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy","volume":"60","author":"Mustjoki","year":"2000","journal-title":"Cancer Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T00:18:04Z","timestamp":1656202684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616302119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":45,"alternative-id":["S0145212616302119"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.09.019","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}